Although the reduction in the incidence of grade 2 to 4 and 3 to 4 aGVHD was in tocilizumab recipients was nonsignificant, there was a strong trend toward a reduction in the incidence of lower GI tract aGVHD.
← all excerpts
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.
2
—
—
The sentences
In contrast with neutrophil engraftment, platelet recovery was a median of 5 days earlier, which approached significance in the multivariate analysis.